Overcoming the shortcomings of oral Parkinson's disease therapy

On October 28, 2021, AbbVie announced that ABBV-951 (foslevodopa/foscarbidopa), a treatment for Parkinson’s disease under development, has reached the primary endpoint in a pivotal phase 3 clinical trial

Parkinson's disease is a progressive neurodegenerative disease caused by the gradual loss of brain cells that produce the neurotransmitter dopamine

In advanced patients, oral levodopa faces a variety of challenges.

ABBV-951 is a prodrug of levodopa and carbidopa

This randomized, double-blind, active-controlled Phase 3 clinical trial enrolled approximately 130 advanced adult patients

The test results showed that at the 12th week, the "Good On" time of the ABBV-951 group increased by 2.

In terms of safety, most adverse events (AEs) in the ABBV-951 group were mild to moderate, with a serious AE rate of 8%, and a serious AE rate of 6% in the oral drug group

Reference materials:

[1] AbbVie Announces ABBV-951 (Foslevodopa/Foscarbidopa) Showed Improvement in Controlling Motor Fluctuations Compared to Oral Levodopa/Carbidopa Medication in Pivotal Phase 3 Trial in Patients with Advanced Parkinson's Disease.

(The original text has been deleted)